Patents by Inventor Malcolm Huestis

Malcolm Huestis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LACTAMS AS CBL-B INHIBITORS SELECTIVE OVER C-CBL
    Publication number: 20230212153
    Abstract: A compound, of formula (I): suitable for treating a cancer wherein the cancer is susceptible to inhibition of Cbl-B.
    Type: Application
    Filed: November 4, 2022
    Publication date: July 6, 2023
    Applicant: Genentech, Inc.
    Inventors: Malcolm HUESTIS, Michael John LAMBRECHT, Jun LIANG, Man Un UNG, Xiaojing WANG, Jason Robert ZBIEG, Bing-Yan Zhu, Lisa Marie BARTON, Fabio BROCCATELLI, Georgette Marie CASTANEDO, Araz JAKALIAN, Robin LAROUCHE-GAUTHIER, Arun YADAV
  • LACTAMS AS CBL-B INHIBITORS
    Publication number: 20230079990
    Abstract: Various lactam compound that binds Cbl-B, many of which are selective for Cbl-B over C-Cbl, and methods of making and using the same.
    Type: Application
    Filed: February 3, 2022
    Publication date: March 16, 2023
    Applicant: Genentech, Inc.
    Inventors: Jun LIANG, Araz JAKALIAN, Michael John LAMBRECHT, Robin LAROUCHE-GAUTHIER, Malcolm HUESTIS, Man Un UNG, Xiaojing WANG, Arun YADAV, Jason Robert ZBIEG, Fabio BROCCATELLI
  • Biheteroaryl compounds and uses thereof
    Patent number: 11129832
    Abstract: The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula I-I all have the meaning as defined herein.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: September 28, 2021
    Assignee: Genentech, Inc.
    Inventors: Anthony Estrada, Liting Dong, Kevin X. Chen, Paul Gibbons, Malcolm Huestis, Terry Kellar, Wen Liu, Changyou Ma, Joseph P. Lyssikatos, Alan G. Olivero, Snahel Patel, Daniel Shore, Michael Siu
  • Naphthyridines as inhibitors of HPK1
    Patent number: 11034692
    Abstract: Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: June 15, 2021
    Assignee: Genentech, Inc.
    Inventors: Bryan Chan, Blake Daniels, Joy Drobnick, Lewis Gazzard, Timothy Heffron, Malcolm Huestis, Jun Liang, Sushant Malhotra, Rohan Mendonca, Naomi Rajapaksa, Michael Siu, Craig Stivala, John Tellis, Weiru Wang, BinQing Wei, Aihe Zhou, Matthew W. Cartwright, Emanuela Gancia, Graham Jones, Michael Lainchbury, Andrew Madin, Eileen Seward, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu, Baihua Hu, Aijun Lu
  • BIHETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20200188397
    Abstract: The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula I-I all have the meaning as defined herein.
    Type: Application
    Filed: October 28, 2019
    Publication date: June 18, 2020
    Applicant: Genentech, Inc.
    Inventors: Anthony Estrada, Liting Dong, Kevin X. Chen, Paul Gibbons, Malcolm Huestis, Terry Kellar, Wen Liu, Changyou Ma, Joseph Lyssikatos, Alan Olivero, Snahel Patel, Daniel Shore, Michael Siu
  • Naphthyridines as inhibitors of HPK1
    Patent number: 10407424
    Abstract: Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: September 10, 2019
    Assignee: Genentech, Inc.
    Inventors: Bryan Chan, Naomi Rajapaksa, Michael Siu, Craig Stivala, John Tellis, Weiru Wang, BinQing Wei, Aihe Zhou, Matthew W. Cartwright, Emanuela Gancia, Graham Jones, Blake Daniels, Michael Lainchbury, Andrew Madin, Eileen Seward, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu, Baihua Hu, Aijun Lu, Joy Drobnick, Lewis Gazzard, Timothy Heffron, Malcolm Huestis, Jun Liang, Sushant Malhotra, Rohan Mendonca
  • Tricyclic DLK inhibitors and uses thereof
    Patent number: 10131675
    Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein ring A and R1-R2 have any of the values defined in the specification. The compounds and salts are useful for treating DLK mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as methods of using said compounds, salts, or compositions as DLK inhibitors and for treating neurodegeneration diseases and disorders.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: November 20, 2018
    Assignee: Genentech, Inc.
    Inventors: Anthony Estrada, Snahel Patel, Terry Kellar, Malcolm Huestis, Daniel Shore, Michael Siu
  • NAPHTHYRIDINES AS INHIBITORS OF HPK1
    Publication number: 20180282328
    Abstract: Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.
    Type: Application
    Filed: March 30, 2018
    Publication date: October 4, 2018
    Applicant: Genentech, Inc.
    Inventors: Bryan Chan, Blake Daniels, Joy Drobnick, Lewis Gazzard, Timothy Heffron, Malcolm Huestis, Jun Liang, Sushant Malhotra, Rohan Mendonca, Naomi Rajapaksa, Michael Siu, Craig Stivala, John Tellis, Weiru Wang, BinQing Wei, Aihe Zhou, Matthew W. Cartwright, Emanuela Gancia, Graham Jones, Michael Lainchbury, Andrew Madin, Eileen Seward, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu, Baihua Hu, Aijun Lu
  • Biheteroaryl compounds and uses thereof
    Patent number: 10010549
    Abstract: The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula I-I all have the meaning as defined herein.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: July 3, 2018
    Assignee: Genentech, Inc.
    Inventors: Anthony Estrada, Liting Dong, Kevin X. Chen, Paul Gibbons, Malcolm Huestis, Terry Kellar, Wen Liu, Changyou Ma, Joseph Lyssikatos, Alan Olivero, Snahel Patel, Daniel Shore, Michael Siu
  • BIHETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20180133219
    Abstract: The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula I-I all have the meaning as defined herein.
    Type: Application
    Filed: January 11, 2018
    Publication date: May 17, 2018
    Applicant: Genentech, Inc.
    Inventors: Anthony Estrada, Liting Dong, Kevin X. Chen, Paul Gibbons, Malcolm Huestis, Terry Kellar, Wen Liu, Changyou Ma, Joseph Lyssikatos, Alan Olivero, Snahel Patel, Daniel Shore, Michael Siu
  • TRICYCLIC DLK INHIBITORS AND USES THEREOF
    Publication number: 20170369510
    Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein ring A and R1-R2 have any of the values defined in the specification. The compounds and salts are useful for treating DLK mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as methods of using said compounds, salts, or compositions as DLK inhibitors and for treating neurodegeneration diseases and disorders.
    Type: Application
    Filed: September 8, 2017
    Publication date: December 28, 2017
    Applicant: Genentech, Inc.
    Inventors: Anthony Estrada, Snahel Patel, Terry Kellar, Malcolm Huestis, Daniel Shore, Michael Siu
  • Substituted dipyridylamines and uses thereof
    Patent number: 9399636
    Abstract: The present invention provides for compounds of Formula I and various embodiments thereof, and compositions comprising compounds of Formula I and various embodiments thereof. In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6, m, n and the C-linked Ring have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula I as DLK inhibitors and for treating neurodegeneration diseases and disorders.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: July 26, 2016
    Assignee: Genentech, Inc.
    Inventors: Frederick Cohen, Malcolm Huestis, Cuong Ly, Snahel Patel, Michael Siu, Xianrui Zhao
  • BIHETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20160052940
    Abstract: The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula I-I all have the meaning as defined herein.
    Type: Application
    Filed: October 29, 2015
    Publication date: February 25, 2016
    Applicant: GENENTECH, INC.
    Inventors: ANTHONY ESTRADA, LITING DONG, KEVIN X. CHEN, PAUL GIBBONS, MALCOLM HUESTIS, TERRY KELLAR, WEN LIU, CHANGYOU MA, JOSEPH LYSSIKATOS, ALAN OLIVERO, SNAHEL PATEL, DANIEL SHORE, MICHAEL SIU
  • SUBSTITUTED DIPYRIDYLAMINES AND USES THEREOF
    Publication number: 20150080367
    Abstract: The present invention provides for compounds of Formula I and various embodiments thereof, and compositions comprising compounds of Formula I and various embodiments thereof. In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6, m, n and the C-linked Ring have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula I as DLK inhibitors and for treating neurodegeneration diseases and disorders.
    Type: Application
    Filed: November 21, 2014
    Publication date: March 19, 2015
    Applicant: Genentech, Inc.
    Inventors: Frederick Cohen, Malcolm Huestis, Cuong Ly, Snahel Patel, Michael Siu, Xianrui Zhao
  • COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES
    Publication number: 20120157448
    Abstract: The invention provides novel tricyclic compounds of Formula I? that inhibit ?-secretase cleavage of APP and are useful as therapeutic agents for treating neurodegenerative diseases.
    Type: Application
    Filed: November 22, 2011
    Publication date: June 21, 2012
    Inventors: Adam Cook, Indrani W. Gunawardana, Kevin W. Hunt, Nicholas C. Kallan, Andrew T. Metcalf, Brad Newhouse, Tony P. Tang, Allen A. Thomas, Michael Siu, Malcolm Huestis, Matthew Volgraf
  • Biheteroaryl compounds and uses thereof
    Patent number: RE47848
    Abstract: The present invention provides for compounds of Formula I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula all have the meaning as defined herein.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: February 11, 2020
    Assignee: Genentech, Inc.
    Inventors: Anthony Estrada, Alan G. Olivero, Snahel Patel, Michael Siu, Joseph Lyssikatos, Malcolm Huestis, Terry Kellar